Eli Lilly and Company (LLY)
NYSE • Healthcare
April 2, 2026 at 20:00 UTC
About Eli Lilly and Company
Eli Lilly and Company is a pharmaceutical manufacturer that discovers, develops, and supplies medicines for conditions managed over long periods and in specialized care. The model connects science with delivery: research feeds trials, approvals lead to scaled production, and medical education supports appropriate use in clinics and hospitals. The company’s priority is continuity — steady supply, clear labeling, and guidance that helps clinicians match therapy to patients. Access programs and country teams adapt to local frameworks while holding to shared safety standards. Digital tools and field support aim to simplify onboarding and monitoring without adding burden to care teams. Within the healthcare sector, Lilly’s role is to make new options feel dependable in daily practice, while continuing to invest in pipelines that can address unmet medical need.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Eli Lilly and Company's Technical Indicators Summary
Eli Lilly presents a mixed technical profile with the market above the 10-day and significantly above the 200-day averages, yet below several medium-term moving averages, and the pivot sits above current price. Momentum is positive on the short look while MACD is noncommittal, and ADX signals a modest trend without strong conviction; ATR shows moderate volatility. OBV is lower, indicating weaker volume support for recent gains. Technical takeaway: the technical state is neutral with short-term strength offset by mixed medium- and long-term signals.
| Indicator | Value |
|---|---|
RSI (14) | 46.28 |
Stochastic %K (14, 3, 3) | 47.84 |
CCI (20) | -2.38 |
WPR (14) | -51.70 |
Momentum (10) | 18.08 |
MFI | 43.27 |
MACD Level (12, 26) | -24.75 |
Bollinger Bands | $856.06 - $1026.49 |
ATR (14) | $29.23 (3.12%) |
ADX (14) | 21.97 |
OBV | 93,277,600 |
Classic Pivot Point | $952.40 |
Fibonacci Pivot Point | $952.40 |
Exponential Moving Averages | $901.05 - $976.64(5 indicators) |
Simple Moving Averages | $897.92 - $1022.37(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
End-of-day sector performance was slightly negative (-0.62%), mildly offsetting stock-specific strength. End-of-day, LLY remains on track for an upcoming update on 30 April, roughly 27 days away. LLY edges higher on FDA approval for Foundayo weight-management pill, ahead of its April 30 update.
Price Change
from $935.62 close
+$0.39
Trading Volume
Below avg (3.3M)
2.7M
vs S&P 500 Today
Strong Underperformance
-19.05%
52-Week Position
Mid-range
61.1%
Updated: April 3, 2026 at 20:02 UTC
Quote Summary
LLY Headlines
Vanguard ETFs Face Rotation and Strategy Shifts
April 4, 2026
US Stocks Rise as Growth Sectors Lead
March 31, 2026
Vanguard shifts to disaggregated SEC reporting
March 26, 2026
Mixed Global Markets and Key Corporate Moves
February 11, 2026